24/7 Market News Snapshot 26 March, 2025 – Actinium Pharmaceuticals, Inc (NYSE:ATNM)

March 26, 2025

DENVER, Colo., 26 March, 2025 (247marketnews.com) – (NYSE:ATNM) are discussed in this article.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has recently garnered significant attention in the market, highlighted by a remarkable surge in its stock price. Starting at $2.04, the shares have risen to $2.275, representing an impressive increase of approximately 44% from the previous close of $1.58. This surge is accompanied by a trading volume of 4.04 million shares, reflecting heightened interest among investors and traders alike.

In conjunction with its strong market performance, Actinium is advancing its clinical programs and strategic initiatives within the biopharmaceutical landscape. During a recent presentation, company leadership showcased the revitalized Actimab-A and Iomab-ACT clinical programs, which are targeting high-potential areas in hematological and solid tumor malignancies, as well as cell and gene therapy conditioning. Anticipated clinical data from these initiatives is expected to be released in 2025, which could open new avenues for treating complex medical conditions.

Chairman and CEO Sandesh Seth expressed optimism regarding the company’s trajectory, stating that the recent developments position Actinium for significant milestones in the coming years. The company plans to initiate a Phase 2/3 trial for Actimab-A, which will be tested in combination with established chemotherapy regimens for relapsed or refractory Acute Myeloid Leukemia (AML). Additionally, innovative applications involving PD-1 inhibitors in solid tumors are in the pipeline.

Actinium’s commitment to enhancing the accessibility of advanced therapies is further demonstrated through the Iomab-ACT program, designed to augment patient access to gene therapies. With the establishment of an in-house radiopharmaceutical manufacturing facility and a robust development pipeline, Actinium Pharmaceuticals stands poised to deliver significant advancements in targeted radiotherapy, ultimately aiming to improve patient outcomes across various complex health challenges.

Related news for (ATNM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.